Edition:
United States

Calmare Therapeutics Inc (CTTC.PK)

CTTC.PK on OTC Markets Group

0.20USD
9 Dec 2016
Change (% chg)

$0.01 (+2.81%)
Prev Close
$0.19
Open
$0.18
Day's High
$0.20
Day's Low
$0.17
Volume
10,255
Avg. Vol
21,872
52-wk High
$0.36
52-wk Low
$0.10

Summary

Name Age Since Current Position

Peter Brennan

60 2012 Independent Chairman of the Board

Conrad Mir

46 2014 President, Chief Executive Officer, Director

Thomas Richtarich

63 2016 Chief Financial Officer

Stephen D'Amato

2015 Chief Medical Officer

Carl O'Connell

53 2013 Director

Rustin Howard

58 2012 Independent Director

Stanley Yarbro

65 2012 Independent Director

Biographies

Name Description

Peter Brennan

Mr. Peter F. Brennan is Independent Chairman of the Board of Calmare Therapeutics Incorporated. He has been a director of our company since June 2011. Peter Brennan, MBA, CFA is a New York based investor who has worked over 30 years in the investment management business as an analyst and portfolio manager. In 2004 Mr. Brennan founded Damel Investors LLC, a private partnership which invests in small technology companies. Since 2005 Mr. Brennan has been a director and a member of the audit committee of Sonomax Technologies Inc., a Montreal based hearing healthcare company. Mr. Brennan received his MBA from the University of Chicago in 1979 and his BA from Haverford College in 1977. He is a member and past Chairman of the Corporate Governance Committee of the New York Society of Security Analysts and received the 2001 Volunteer of the Year award from the NYSSA. Mr. Brennan was a member of the US Advocacy Committee of the CFA Institute and was a founding member of the Capital Markets Policy Council of the CFA Institute for Market Integrity, the global advocacy committee of the CFA Institute.

Conrad Mir

Mr. Conrad F. Mir is President, Chief Executive Officer, Director of Calmare Therapeutics Incorporated. Mr. Mir has over twenty years of investment banking, financial structuring, and corporate reengineering experience. He has served in various executive management roles and on the Board of Directors of several companies in the biotechnology industry. Most recently, Mr. Mir was CFO of Pressure BioSciences, Inc., a sample preparation company advancing its proprietary pressure cycling technology. Before that, he was chairman and CEO of Genetic Immunity, Inc., a plasmid, DNA company in the HIV space, and was the executive director of Advaxis, Inc., a vaccine company. Over the last five years, he was responsible for raising more than $40 million in growth capital and broadening corporate reach to new investors and current shareholders. Conrad has worked for several investment banks including Sanford C. Bernstein, First Liberty Investment Group, and Nomura Securities International. He holds a BS/BA in Economics and English with special concentrations in Mathematics and Physics from New York University. He is a classically trained pianist and teacher, and a student of the martial arts.

Thomas Richtarich

Mr. Thomas P. Richtarich is Chief Financial Officer of Calmare Therapeutics Incorporated. He has held roles in corporate financial management for public and privately held companies for over twenty years. Since 2013, Mr. Richtarich has run his own consulting firm, Richtarich Consulting, serving as Chief Financial Officer for his clients and providing assistance to clients in the areas of financial management, strategic planning, capital fund raising, compensation/benefits, talent management and marketing. During 2014 through 2015, Mr. Richtarich also served as Director of Finance, HR and Administration and Chief Financial Officer to Readme Systems, Inc., a privately held company, where his efforts lead to the revitalization of the company through new capital raises and employee recruitment. From 2009 through 2013, Mr. Richtarich served as Director and Corporate Secretary- Human Resources and Administration of Transwitch Corporation, a public company. During this role, Mr. Richtarich managed strategic restructuring, compliance with SEC requirements, benefits programs and talent acquisition. Mr. Richtarich began his professional carrier in various positions in strategic planning, marketing and sales each providing him with progressively increasing leadership and management opportunities. Mr. Richtarich received his BA in Political Science from Fairfield University and his MBA from the University of Connecticut Graduate School of Business.

Stephen D'Amato

Dr. Stephen J. D'Amato, M.D., is Chief Medical Officer of Calmare Therapeutics Incorporated. He has been practicing medicine in Rhode Island for 35 years. Over the past six years, he has been the foremost Calmare® Pain Therapy Device practitioner with over 1000 patients treated in his medical practice. His efforts with Calmare have established new innovative ways of treating many different chronic pain diagnoses including Chemotherapy-induced Peripheral Neuropathy (CIPN), Complex Regional Pain Syndrome (CRPS), Failed Back Surgery Syndrome (FBSS) and Phantom Limb Pain Syndrome. Dr. D’Amato will oversee all medical treatment issues and research topics regarding Calmare, globally. Dr. D’Amato received his medical degree from the University of Padua – Italy in 1976. He is a licensed medical doctor in Rhode Island, Massachusetts and Florida. He attained Fellow status after his first board certification process in Emergency Medicine, and granted “lifelong status” after his third certification as a Fellow of the American College of Emergency Physicians (FACEP). He is also a managing partner of CALMARx Pain Relief, LLC, in West Warwick, RI.

Carl O'Connell

Mr. Carl D. O'Connell is Director of Calmare Therapeutics Incorporated. Mr. O’Connell has 30 years of experience in the healthcare field and 20 years as a leader in the medical device arena. Prior to joining Competitive Technologies, Mr. O’Connell held executive positions for top global medical device and Fortune 500 companies. He recently served as president and CEO for the US Healthcare Division MedSurg for ITOCHU, a Japanese conglomerate, vice president of global marketing for Stryker Spine, and president of Carl Zeiss Surgical, the market leader in optical digital solutions for Neurosurgery, Spine, Ophthalmology, ENT and Dentistry.

Rustin Howard

Mr. Rustin R. Howard is Independent Director of Calmare Therapeutics Incorporated. Mr. Howard is the chairman of the Board of Directors Deep Gulf, Inc., which builds underwater pipelines and associated facilities in deep and ultra-deep offshore oil and gas production fields. Additionally, he is a principal of Whitesand Investments LLC, an “Angel investment” organization, and a co-owner and officer of Silver Bullet Technology. Silver Bullet Technology, where he has been primarily responsible for corporate and financial oversight as well as strategic planning, manufactures and sells software for the banking and payment processing industry. In 1990, he founded and served as CEO and Chairman of the Board of Directors of Phyton, Inc., a world leader in the use of proprietary plant cell fermentation technology, including the production of paclitaxel, the active ingredient of Bristol-Myers Squibb's (NYSE:BMY) multi-billion dollar anticancer drug, Taxol®. Phyton was sold to DFB Pharmaceuticals, Inc. in 2003. Previously, Mr. Howard served as president and CEO of BioWorks Inc., a biotechnology company he founded to develop, produce, and sell products that replace chemical pesticides. Mr. Howard earned his MBA from Cornell University's Johnson Graduate School of Management, where he focused his studies on entrepreneurship, and managing innovation and technology.

Stanley Yarbro

Dr. Stanley K. Yarbro, Ph.D., is Independent Director of the Company. Mr. Yarbro has extensive experience in market development of high technology solutions to a worldwide customer base. He recently retired as executive vice president, worldwide field operations, for Varian Semiconductor Equipment Associates, a position he had held since 2004. Prior to Varian, Dr. Yarbro served in various executive capacities at KLA-Tencor Corporation, in the semi-conductor industry. He currently serves on the boards of FSI International and Carbon Design Innovations and has previously served on the boards of Electrogas, Inc. and Molecular Imaging where he worked closely with the organizations to develop and improve sales and marketing strategies. Dr. Yarbro holds a Ph.D. in Analytical Chemistry from Georgia Institute of Technology and a B.S.in Chemistry from Wake Forest University.

Basic Compensation

Name Fiscal Year Total

Peter Brennan

--

Conrad Mir

270,000

Thomas Richtarich

--

Stephen D'Amato

--

Carl O'Connell

569,000

Rustin Howard

--

Stanley Yarbro

--
As Of  30 Dec 2014